Immunotherapy plus chemotherapy for advanced stomach, bile duct, or cervical cancer
Treatments studied
Part of Cancer, Digestive system, Women’s health & pregnancy clinical trials.
This trial tests a combination of an immunotherapy drug (pembrolizumab, also known as Keytruda) with chemotherapy or chemoradiotherapy for people in India with certain advanced cancers of the stomach, bile ducts, or cervix. The goal is to see if adding immunotherapy helps control the cancer better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancers: stomach or gastroesophageal junction cancer, bile duct or gallbladder cancer, or cervical cancer.
- Your cancer must be advanced (spread) or not removable with surgery (for stomach or bile duct cancers). For cervical cancer, it must be high-risk and locally advanced.
- For stomach cancer, your tumor must test positive for a protein called PD-L1 (CPS score of 1 or higher) and be HER2-negative.
- You cannot have had prior chemotherapy or other systemic therapy for advanced cancer (except for stomach/bile duct where only prior surgery or radiation is allowed).
- You must not have active infections like HIV, tuberculosis, hepatitis B or C (unless well-controlled), or active autoimmune disease.
- You cannot have low potassium, magnesium, or calcium levels, or a history of lung inflammation (pneumonitis) that needed steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for locally advanced stomach cancer. It uses a heated chemotherapy bath (HIPEC) before giving a combination of two chemotherapy drugs (SOX or XELOX) plus an immunotherapy drug called serplulimab. This aims to shrink the tumor and improve the chances of successful surgery and long-term control.
This study tests a new type of gene therapy (OBP-301) injected directly into the tumor, combined with the immunotherapy drug Keytruda (pembrolizumab), for people with advanced stomach, junction, or esophageal cancer. Researchers want to see if this combination can help when standard treatments have stopped working.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This trial tests a combination of two treatments: an immunotherapy drug (pembrolizumab, which helps your immune system fight cancer) and chemotherapy (FLOT) for advanced stomach or esophageal junction cancer. The goal is to see if this combination is safe and works better than standard care.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
Hear when a new Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.